Alignment Healthcare CFO sells $226,661 in stock

Published 13/03/2025, 22:06
Alignment Healthcare CFO sells $226,661 in stock

Robert Thomas Freeman, the Chief Financial Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), a $2.96 billion healthcare company whose stock has surged 214% over the past year, recently sold shares of the company’s stock, according to a regulatory filing made on March 13, 2025. The transactions, which occurred on March 12, involved the sale of 14,692 shares of common stock, totaling approximately $226,661. The shares were sold at a weighted-average price range between $15.4231 and $15.7379 per share, with the stock currently trading near its 52-week high of $16.25. According to InvestingPro, analysts maintain a bullish outlook on ALHC with a consensus Buy rating.

Following these transactions, Freeman holds 1,402,862 shares directly. Additionally, he has indirect ownership of 92,929 shares through FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, of which Freeman is an indirect beneficiary.

The sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, and were not discretionary trades by Freeman.

In other recent news, Alignment Healthcare reported strong fourth-quarter 2024 earnings, beating analysts’ expectations with an EPS of -0.16 against a forecast of -0.18. The company also exceeded revenue projections, achieving $701.2 million compared to the anticipated $674.97 million. For the full year, Alignment Healthcare’s revenue reached $2.7 billion, marking a 48% year-over-year increase, while membership grew by 59%, driven by expansion beyond California. Looking ahead, the company provided 2025 revenue guidance between $3.72 billion and $3.78 billion, with an adjusted gross profit expected to range from $415 million to $445 million.

Analysts have shown confidence in Alignment Healthcare’s potential, with Piper Sandler raising the price target to $21.00 and maintaining an Overweight rating, citing the company’s scalable "flywheel" approach. Similarly, Raymond (NSE:RYMD) James increased the price target to $19.00 and reiterated a Strong Buy rating, following the company’s robust fourth-quarter performance. The firm’s strategies, particularly its high Star Ratings, are credited with improving patient engagement and reducing costs, which contribute to better member retention and quality bonus payments.

These developments suggest a promising outlook for Alignment Healthcare, with the company focusing on expanding its market presence and enhancing profitability. The company’s guidance for 2025 anticipates significant growth, with health plan membership expected to reach between 227,000 and 233,000 members. Analysts from Raymond James highlighted the company’s ability to grow at a rate of 20% or more annually while improving EBITDA profitability, leveraging its clinical model and operational scale.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.